

Original article:

Effect of thrombolysis in STEMI patient coming to PRH, Loni.

Dr Gulshan Tolani , Dr S N Mahajan

Department of Medicine, Rural Medical College, PIMS (DU) Loni

Corresponding author*

Abstract

Introduction: Thrombus causes closure of vessels in acute myocardial infarction and compromises flow in unstable angina. Successful epicardial vessel thrombolysis is necessary for better prognosis, but the outcome more strongly correlates with the micro vascular flow.

Study Methodology: The duration of our study was 5 months from September 2017 to February 2018. The study included data of 70 diagnosed cases of ST elevation Myocardial Infarction admitted in PRH, Loni. Diagnosis of STEMI in symptomatic patients was based on the ECG criteria.

Results and Conclusion: The Thrombolysis in Myocardial Infarction Trial shows a median time of 30 min from administration to the establishment of grade 2 or 3 coronary flow in patients successfully reperfused using thrombolytic agents.

Introduction:

Thrombus causes closure of vessels in acute myocardial infarction and compromises flow in unstable angina. Successful epicardial vessel thrombolysis is necessary for better prognosis, but the outcome more strongly correlates with the micro vascular flow. ST segment on ECG is a better indicator of prognosis. When there is occlusion of an epicardial coronary artery, ST elevation is shown on ECG which is electrical manifestation of the patho physiological changes and is known as ST-Elevation Myocardial Infarction (STEMI). Although cardiac arrest initiated by intracoronary thrombosis in situ is different from the mechanisms associated with pulmonary thromboembolism, thrombolysis has proved to be an effective treatment strategy for both these diseases . With this view present study was planned to find out the efficacy of thrombolytic therapy of STEMI patient.

Study Methodology:

The duration of our study was 5 months from September 2017 to February 2018. The study included data of 70 diagnosed cases of ST elevation Myocardial Infarction admitted in PRH, Loni. Diagnosis of STEMI in symptomatic patients was based on the ECG criteria. The established criteria of Myocardial Infarction which defines STEMI as new ST elevation at the J point in at least 2 contiguous leads of ≥ 2 mm (0.2 mV) in men or ≥ 1.5 mm (0.15 mV) in women in leads V2–V3 and/or of ≥ 1 mm (0.1 mV) in other contiguous chest leads or the limb leads.

Inclusion criteria

Admission to the coronary care unit

- 1) Patient willing to give consent.
- 2) Patient's age more or equal to 30 years.
- 3) ECG showing ST elevation myocardial infarction.

- 4) CK MB LEVELS raised.
- 5) Patient thrombolysed with streptokinase within 30 minutes of admission.

Exclusion criteria

- 1) Patient not willing for consent.
- 2) Previous history of ischemic heart disease or any other heart disease.
- 3) No elevation of ST segment.
- 4) Any active bleeding tendency.

Results:

Table No 01: Age wise distribution of the patients

Sr. No.	Age Groups (Yrs)	Frequency (%)
01	≤ 40	07 (10.0%)
02	41 to 50	06 (08.6%)
03	51 to 60	14 (20.0%)
04	≥ 60	43 (61.4%)
	Total	70 (100%)

The Thrombolysis in Myocardial Infarction Trial shows a median time of 30 min from administration to the establishment of grade 2 or 3 coronary flow in patients successfully reperfused using thrombolytic agents.

Discussion:

From the clinical point of view left ventricular remodeling is a dynamic process, starting in the acute phase of myocardial infarction (MI) with infarct expansion-that is, rearrangement of wall structure leading to myocardial thinning and lengthening, and progressing to left ventricular dilation and hypertrophy, the development of infarct expansion commonly precedes myocardial rupture and denotes a worsened prognosis.¹

Left ventricular infarct expansion in the early phase of acute myocardial infarction is produced by myocardial structural changes such as myocyte necrosis, slippage, or rupture, and reduction in the intercellular space,² which result in infarct segment lengthening and wall thinning.³

Interventions that aim to improve outcome in cardiac arrest have proved to be disappointing. In particular, no drug has been reliably proved to increase survival to discharge after cardiac arrest . Given that coronary thrombosis in situ is implicated in a large proportion of patients with cardiac arrest, the use of thrombolytic agents has been suggested. When considering the potential benefits of thrombolysis in cardiac arrest, it is equally important to explore the risk. Many clinical guidelines list prolonged CPR as a contraindication for thrombolysis.

However, there was a significant difference in the prevalence of in-hospital mortality between those patients with acute anterior STEMI who developed early left ventricular infarct expansion compared with patients with acute STEMI without left ventricular infarct expansion.

Conclusion:

The Thrombolysis in Myocardial Infarction Trial shows a median time of 30 min from administration to the establishment of grade 2 or 3 coronary flow in patients successfully reperfused using thrombolytic agents.

References:

- 1) Schröder K, Zeymer U, Wegschneider K, Schroder R. Prediction of outcome in ST elevation myocardial infarction by the extent of ST segment deviation recovery. Which method is best. *Z Kardiol.* 2004;93:595–604.
2. Van de Werf F, Ardissino D, Betriu A. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task force on the management of acute myocardial infarction of the European Society of Cardiology. *Eur Heart J.* 2003;24:28–66.
3. Khurram M, Khaar HB, Javed S, Hasan Z, Goraya F, Haq UU. Acute myocardial infarction: experience at a teaching hospital. *J Rawal Med Coll.* 2002;6:65–69.
4. American Heart Association. Cardiovascular Disease Statistics. 2006
5. Jafar TH, Jafary FH, Jessani S, Chaturvedi N. Heart disease epidemic in Pakistan: women and men at equal risk. *Am Heart J.* 2005;150:221–226.
6. Kloner RA, Rezkalla SH. Cardiac protection during acute myocardial infarction: where do we stand in 2004. *J Am Coll Cardiol.* 2004;44:276–286.
7. Topol EJ. Acute myocardial infarction: thrombolysis. A current overview of the benefits and limitations of thrombolytic strategies and the move towards combining thrombolytic agents with glycoprotein IIb/IIIa receptor blockers. *Heart.* 2000;83:122–126.